Antibiotics affect bacteria by targeting essential biological processes: building the cell wall, making proteins, or copying DNA. Each antibiotic class attacks a specific piece of cellular machinery that bacteria need to survive or reproduce, and the result is either death or a halt in growth. Because these targets are unique to bacterial cells or work differently enough from human cells, antibiotics can destroy an infection without damaging your own tissue.
Breaking the Cell Wall
Bacteria are surrounded by a rigid wall made of a mesh-like material called peptidoglycan, which keeps the cell from bursting under its own internal pressure. Penicillins, cephalosporins, and related antibiotics (collectively called beta-lactams) permanently disable the enzymes responsible for stitching this mesh together. The antibiotic molecule locks onto the enzyme’s active site, forming a bond so stable the enzyme never recovers. Without fresh cross-links being added, the wall weakens as the bacterium grows. Eventually, water rushes in through the compromised structure and the cell ruptures. This is why beta-lactams are among the most effective bacteria-killing antibiotics: they don’t just stop growth, they cause the cell to self-destruct.
Another class, the glycopeptides (vancomycin is the best known), takes a different angle on the same target. Instead of disabling the enzyme directly, vancomycin physically blocks the building blocks of the wall so the enzymes can’t reach them. The end result is the same: a fatally weakened wall.
Shutting Down Protein Production
Bacteria build proteins using molecular machines called ribosomes, which read genetic instructions and assemble amino acids into chains. Bacterial ribosomes are structurally different from human ribosomes, making them a prime target. Two broad groups of antibiotics attack different halves of this machine.
Tetracyclines bind to the smaller half of the ribosome and physically block the arrival of new amino acids. Think of it as putting a cap over the loading dock. Without fresh building materials coming in, the protein chain can’t grow. Aminoglycosides (like gentamicin and streptomycin) also bind the smaller half, but their effect is more destructive. They warp the shape of a key reading site, causing the ribosome to misread the genetic code. The cell then produces defective, nonfunctional proteins. Aminoglycosides also prevent the ribosome from moving along the genetic message and from being recycled after finishing a protein, compounding the damage.
Macrolides and several other classes target the larger half of the ribosome. They physically obstruct the tunnel through which a growing protein chain exits, stalling production in its tracks.
Blocking DNA and RNA
To divide, a bacterium must copy its DNA. To use that DNA, it must transcribe it into RNA. Antibiotics can interfere with both steps.
Fluoroquinolones target two enzymes that manage the coiling and uncoiling of bacterial DNA during replication. These enzymes normally cut the DNA strand, unwind it, and rejoin it. Fluoroquinolones trap the enzymes mid-cut, leaving the DNA broken. The cell cannot repair this damage fast enough and dies. Rifamycins, the class that includes the tuberculosis drug rifampin, take aim at RNA polymerase, the enzyme that reads DNA and produces RNA. By binding deep inside the enzyme’s channel, rifamycins prevent it from generating the RNA instructions the cell needs to function.
Starving Bacteria of Essential Nutrients
Some antibiotics work by cutting off a metabolic supply line rather than attacking a structure directly. Sulfonamides and trimethoprim both disrupt the production of folic acid, a vitamin that bacteria need to build DNA and grow. Human cells can’t make folic acid at all; we absorb it from food. Bacteria must synthesize their own. This difference is what makes these drugs selective: they starve bacteria of something essential while leaving your cells completely unaffected.
Killing vs. Stopping Growth
Not all antibiotics destroy bacteria outright. The distinction matters for how infections clear. Bactericidal antibiotics, like beta-lactams, fluoroquinolones, and aminoglycosides, actively kill bacterial cells. They cause irreversible damage, whether that’s a ruptured wall or shattered DNA. Bacteriostatic antibiotics, like tetracyclines, macrolides, and oxazolidinones, halt bacterial growth without directly killing. They hold the population in check while your immune system finishes the job. In a healthy person, both approaches resolve most infections effectively. In someone with a weakened immune system, bactericidal drugs are sometimes preferred because they don’t rely as heavily on the body’s own defenses.
Why Some Bacteria Are Naturally Harder to Kill
The structure of a bacterium’s outer layers determines which antibiotics can reach their targets. Gram-positive bacteria have a single membrane surrounded by a thick peptidoglycan wall. This wall is porous enough that most small antibiotic molecules pass through easily. Gram-negative bacteria have a thinner wall but add a second, outer membrane coated with a dense layer of molecules called lipopolysaccharides. This outer membrane acts as a selective barrier, blocking many antibiotics that work perfectly well against gram-positive species.
Gram-negative bacteria also deploy efflux pumps, molecular machines that actively push antibiotics back out of the cell before they can accumulate to effective levels. The combination of a double-membrane barrier and active pumping explains why gram-negative infections are generally harder to treat and why they require specific antibiotic classes designed to penetrate or bypass these defenses.
How Bacteria Fight Back
Bacteria evolve resistance through four main strategies. First, they can produce enzymes that break down or chemically modify the antibiotic, rendering it useless before it reaches its target. Second, they can alter the target itself so the antibiotic no longer fits. Third, they can reduce permeability by changing the proteins in their outer membrane, limiting how much antibiotic enters the cell. Fourth, they can ramp up efflux pumps to expel antibiotics faster than they accumulate.
These mechanisms can be inherited or shared between bacteria through small rings of DNA called plasmids, which means resistance can spread rapidly through a bacterial population and even jump between species. A 2024 analysis published in The Lancet estimated that in 2021, 4.71 million deaths worldwide were associated with antibiotic-resistant bacterial infections, with 1.14 million directly caused by resistance. While resistance-related deaths in children under five dropped by more than 50% between 1990 and 2021, deaths in adults over 70 increased by more than 80% over the same period.
Collateral Damage to Beneficial Bacteria
Antibiotics don’t distinguish between harmful bacteria and the trillions of beneficial microbes living in your gut. A standard course can significantly reduce the diversity of your gut community, and recovery isn’t always complete. Research in animal models has shown that after antibiotic treatment, overall microbial diversity slowly climbs back but often stabilizes at a level significantly lower than before treatment. One major group of gut bacteria, Bacteroidetes, showed permanent diversity losses of 36% to 70% depending on the antibiotic used. These weren’t temporary dips; they reflected the outright extinction of sensitive species that never returned, even when the antibiotic was removed and conditions were favorable for regrowth.
This loss of diversity has practical implications. A less diverse gut microbiome is associated with increased susceptibility to future infections, digestive problems, and broader immune effects. It’s one reason finishing a prescribed course matters (to actually clear the infection) but also why antibiotics shouldn’t be used when they aren’t needed.